| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Daniella Rylander, Alessandra Recchia, Flora Mela, Andrzej Dekundy, Wojciech Danysz, M Angela Cenc. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. The Journal of pharmacology and experimental therapeutics. vol 330. issue 1. 2009-07-27. PMID:19357321. |
l-dopa-induced dyskinesia (lid) in parkinson's disease has been linked to altered dopamine and glutamate transmission within the basal ganglia. |
2009-07-27 |
2023-08-12 |
rat |
| M G Morgese, T Cassano, S Gaetani, T Macheda, L Laconca, P Dipasquale, L Ferraro, T Antonelli, V Cuomo, A Giuffrid. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochemistry international. vol 54. issue 1. 2009-04-24. PMID:19010365. |
our data indicate that: (1) the 6-hydroxydopamine lesion decreases dopamine turnover in the denervated striatum; (2) levodopa injection reduces extracellular glutamate in the side ipsilateral to the lesion of dyskinetic rats; (3) sub-chronic win55,212-2 prevents levodopa-induced glutamate volume transmission unbalances across the two hemispheres; and (4) levodopa-induced dyskinesias are inversely correlated with glutamate levels in the denervated striatum. |
2009-04-24 |
2023-08-12 |
rat |
| A R Troiano, R de la Fuente-Fernandez, V Sossi, M Schulzer, E Mak, T J Ruth, A J Stoess. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology. vol 72. issue 14. 2009-04-24. PMID:19020294. |
pet demonstrates reduced dopamine transporter expression in pd with dyskinesias. |
2009-04-24 |
2023-08-12 |
Not clear |
| Kristin B Dupre, Karen L Eskow, Christopher J Barnum, Christopher Bisho. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology. vol 55. issue 8. 2009-04-15. PMID:18824001. |
convergent evidence suggests that serotonin 5-ht1a receptor (5-ht1ar) agonists reduce l-dopa-induced dyskinesia by auto-regulating aberrant release of l-dopa-derived dopamine (da) from raphestriatal neurons. |
2009-04-15 |
2023-08-12 |
rat |
| Peter Jenne. Molecular mechanisms of L-DOPA-induced dyskinesia. Nature reviews. Neuroscience. vol 9. issue 9. 2009-04-09. PMID:18714325. |
a reinterpretation of recent data suggests that priming for dyskinesia results from nigral denervation and the loss of striatal dopamine input, which alters glutamatergic synaptic connectivity in the striatum. |
2009-04-09 |
2023-08-12 |
Not clear |
| Takahiro Iizuk. [Clinical features and pathogenesis of anti-NMDA receptor encephalitis]. Rinsho shinkeigaku = Clinical neurology. vol 48. issue 11. 2009-04-08. PMID:19198118. |
this results in disinhibition of postsynaptic glutamatergic transmission, excessive release of glutamate in the prefrontal/subcortical structures, and glutamate and dopamine dysregulation that might contribute to development of schizophrenia-like psychosis and bizarre dyskinesias. |
2009-04-08 |
2023-08-12 |
Not clear |
| A N Boiko, T T Batysheva, N G Minaeva, L A Babina, T V Vdovichenko, E Yu Zhuravleva, R K Shikhkerimov, E A Malykhina, A A Khozova, K A Zaitsev, E V Kostenk. Use of the new levodopa agent Stalevo (levodopa/carbidopa/entacapone) in the treatment of Parkinson's disease in out-patient clinical practice (the START-M open trial). Neuroscience and behavioral physiology. vol 38. issue 9. 2009-04-02. PMID:18975095. |
despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2-3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant (physiological) stimulation of postsynaptic dopamine receptors. |
2009-04-02 |
2023-08-12 |
Not clear |
| Anthony E Lan. When and how should treatment be started in Parkinson disease? Neurology. vol 72. issue 7 Suppl. 2009-03-12. PMID:19221313. |
dopamine agonists are clearly associated with a reduction in the incidence of dyskinesias in the early years, but it is not certain that this translates into long-term benefit. |
2009-03-12 |
2023-08-12 |
Not clear |
| Thomas Carlsson, Manolo Carta, Ana Muñoz, Bengt Mattsson, Christian Winkler, Deniz Kirik, Anders Björklun. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain : a journal of neurology. vol 132. issue Pt 2. 2009-03-10. PMID:19039008. |
impact of grafted serotonin and dopamine neurons on development of l-dopa-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. |
2009-03-10 |
2023-08-12 |
rat |
| Thomas Carlsson, Manolo Carta, Ana Muñoz, Bengt Mattsson, Christian Winkler, Deniz Kirik, Anders Björklun. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain : a journal of neurology. vol 132. issue Pt 2. 2009-03-10. PMID:19039008. |
here, we have studied the impact of grafted serotonin neurons--alone or mixed with dopamine neurons--on the development of l-dopa-induced dyskinesia in rats with a partial 6-hydroxydopamine lesion of the host nigrostriatal projection. |
2009-03-10 |
2023-08-12 |
rat |
| Thomas Carlsson, Manolo Carta, Ana Muñoz, Bengt Mattsson, Christian Winkler, Deniz Kirik, Anders Björklun. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain : a journal of neurology. vol 132. issue Pt 2. 2009-03-10. PMID:19039008. |
interestingly, rats with grafts that contained a mixture of dopamine and serotonin neurons (in approximately 2:1) showed a marked reduction in l-dopa-induced dyskinesia over time, and the appearance of severe dyskinesia induced by the removal of the residual dopamine innervation, seen in the animals with transplants of serotonin neurons alone, was blocked. |
2009-03-10 |
2023-08-12 |
rat |
| Thomas Carlsson, Manolo Carta, Ana Muñoz, Bengt Mattsson, Christian Winkler, Deniz Kirik, Anders Björklun. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain : a journal of neurology. vol 132. issue Pt 2. 2009-03-10. PMID:19039008. |
these data indicate that as long as a sufficient portion, some 10-20%, of the dopamine innervation still remains, the increased host serotonin innervation generated by the grafted serotonin neurons will have limited effect on the development or severity of l-dopa-induced dyskinesias. |
2009-03-10 |
2023-08-12 |
rat |
| Thomas Carlsson, Manolo Carta, Ana Muñoz, Bengt Mattsson, Christian Winkler, Deniz Kirik, Anders Björklun. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain : a journal of neurology. vol 132. issue Pt 2. 2009-03-10. PMID:19039008. |
at more advanced stages of the disease, when the dopamine innervation of the putamen is reduced below this critical threshold, grafted serotonin neurons are likely to aggravate l-dopa-induced dyskinesia in those cases where the dopamine re-innervation derived from the grafted neurons is insufficient in magnitude or do not cover the critical dyskinesia-inducing sub-regions of the grafted putamen. |
2009-03-10 |
2023-08-12 |
rat |
| Thomas Carlsson, Manolo Carta, Ana Muñoz, Bengt Mattsson, Christian Winkler, Deniz Kirik, Anders Björklun. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain : a journal of neurology. vol 132. issue Pt 2. 2009-03-10. PMID:19039008. |
we conclude that it is not the absolute number of serotonin neurons in the grafts, but the relative densities of dopamine and serotonin innervations in the grafted striatum that is the critical factor in determining the long-term effect of foetal tissue graft, beneficial or detrimental, on dyskinesia in grafted parkinson's disease patients. |
2009-03-10 |
2023-08-12 |
rat |
| I A Prescott, J O Dostrovsky, E Moro, M Hodaie, A M Lozano, W D Hutchiso. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients. Brain : a journal of neurology. vol 132. issue Pt 2. 2009-03-10. PMID:19050033. |
the dopamine precursor levodopa (l-dopa) is the most effective treatment for the amelioration of parkinson's disease signs and symptoms, but long-term administration can lead to disabling motor fluctuations and l-dopa -induced dyskinesias (lids). |
2009-03-10 |
2023-08-12 |
rat |
| Christelle Monville, Eduardo M Torres, Vladimir Pekarik, Emma L Lane, Stephen B Dunnet. Genetic, temporal and diurnal influences on L-dopa-induced dyskinesia in the 6-OHDA model. Brain research bulletin. vol 78. issue 4-5. 2009-03-06. PMID:19070653. |
the neural mechanisms that underlie dyskinesia are far from clear but they have been associated with pulsatile stimulation of dopamine receptors, downstream changes in proteins and genes, and abnormalities in non-dopamine transmitter systems. |
2009-03-06 |
2023-08-12 |
human |
| M Giorgi, V D'Angelo, Z Esposito, V Nuccetelli, R Sorge, A Martorana, A Stefani, G Bernardi, G Sancesari. Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. The European journal of neuroscience. vol 28. issue 5. 2009-03-05. PMID:18717735. |
dysregulation of dopamine receptors is thought to underlie levodopa-induced dyskinesias in experimental models of parkinson's disease. |
2009-03-05 |
2023-08-12 |
rat |
| Peter Jenne. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities. Movement disorders : official journal of the Movement Disorder Society. vol 23 Suppl 3. 2009-02-13. PMID:18781676. |
loss of tonic stimulation of striatal dopamine receptors in pd and its replacement by pulsatile dopaminergic stimulation using short acting drugs has been proposed as leading to the abnormalities that cause dyskinesia induction. |
2009-02-13 |
2023-08-12 |
Not clear |
| Peter Jenne. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities. Movement disorders : official journal of the Movement Disorder Society. vol 23 Suppl 3. 2009-02-13. PMID:18781676. |
as a consequence, the concept of continuous dopaminergic stimulation (cds) was introduced to explain why longer acting dopamine agonists do not produce the same intensity of dyskinesia. |
2009-02-13 |
2023-08-12 |
Not clear |
| Peter Jenne. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities. Movement disorders : official journal of the Movement Disorder Society. vol 23 Suppl 3. 2009-02-13. PMID:18781676. |
comparison of the ability to induce dyskinesia of the same dopamine agonists given by pulsatile or continuous administration or more constant administration of levodopa (l-dopa) has shown that constant drug delivery (cdd) dramatically reduces dyskinesia induction. |
2009-02-13 |
2023-08-12 |
Not clear |